A phase III trial investigating the efficacy and safety of Grazax in children aged 5-16 years with grass pollen induced rhinoconjunctivitis with or without asthma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Timothy grass pollen allergen extract (Grastek) (Primary)
Indications Allergic asthma; Allergic rhinitis; Grass pollen hypersensitivity; Rhinoconjunctivitis
Focus Therapeutic Use

17 Mar 2008 Results have been presented at the AAAAI 2008, according to an ALK-Abello media release.
22 Jun 2007 Status change from recruiting to in progress
30 Dec 2006 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com